Genmab — April 2021
-
...ok - for some odd reason, patients prefer to pay for the drug rather than to get it for free
-
It only makes sense to me if Novartis have confused those numbers - and percentage sales goes from 65% to 75%.
-
Do you know when the “bridging program” ends? Sounds like Q3
-
It certainly sounds like there is a long tail of “free sales” in those numbers
-
Sanofi: First-quarter Sarclisa
sales were €34 million driven by
additional country launches. First-quarter sales in the U.S. and in Europe were €12 million and €13 million, respectively.
In Rest of the World sales (€9 million) were driven by a strong performance in Japan. -
So, basically what they are saying is H1 paid sales have surprised us, but we leave guidance for H2 paid sales unchanged - that is why this “percentage sales” will decrease...?
-
Makes sense in a very arse-backwards-we-insist-on-not-making-sense sort of way...
-
in real numbers, lets say Q2 will grow to for example 75M. Then H1 ends up at 125M. To make their % correct we would need 230M in H2 to get to 65%. So that would total full year sales at 355M. So i think we can use something like that for now as 2021 estimate
-
Sorry. Had to step out to learn the missus to handle the motorbike. Your calcs defininately sound right. Thanks for that!
-
Learn/teach.
-
That I cannot - don’t know where to find it
they must have been able to divert more patients to programs that don't benefit from the free sales
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind